MOTHER MEDTRONIC THORACIC ENDOVASCULAR REGISTRY

Investigation of Stent Grafts in the Treatment of Acute and Chronic Aortic Thoracic Pathologies

TEVAR OFFERS MIDTERM PROTECTION


from Aortic-Related Mortality in 1,000+ Patient Analysis

SOURCES OF INFORMATION THAT COMPRISED THE MOTHER DATABASE				
Trial	No. Patients	Device Evaluated	Follow- Up	
VALOR	359	Talent	5Y	
VALORII	160	Valiant	5Y	
Valiant Captivia Registry	68	Valiant Captivia	3Y	
VIRTUE	100	Valiant Xcelerant	3Y	
INSTEAD	100	Talent	5Y	
St. George's Vascular Institute	223	Talent/Valiant	Variable	

Source: Information from studies conducted in the U.S. and the EU. The Talent $^{\!\!\!\top}$ thoracic stent graft is no longer commercially available in the U.S.

MOTHER DATABASE:

Patients Treated, Stratified According to Presenting Pathology



STUDY CONCLUSION

- Acute and chronic aortic dissection patients have low rates of aortic-related mortality in the midterm after TEVAR*
- TEVAR offers excellent midterm protection from aortic-related mortality for both TAA and type B aortic dissection
- Aortic-related mortality markedly plateaus following the peri-operative phase, suggesting that TEVAR may prevent aortic dissection and rupture



Parker JD, Golledge J. Outcome of endovascular treatment of acute type B aortic dissection. Ann Thorac Surg. 2008;86:1707–1712. Trimarchi S, Nienaber CA, Rampoldi V, Myrmel T, Suzuki T, Bossone E, Tolva V, Deeb MG, Upchurch GR Jr, Cooper JV, Fang J, Isselbacher EM, Sundt TM III, Eagle KA; IRAD Investigators. Role and results of surgery in acute type B aortic dissection: insights from the International Registry of Acute Aortic Dissection (IRAD). Circulation. 2006;114:1357–1364. Walsh SR, Tang TY, Sadat U, et al. Endovascular stenting versus open surgery for thoracic aortic disease: systematic review and meta-analysis of perioperative results. J Vasc Surg. 2008;47:1094–1098.e3. Source: Patterson, B. et. al. Circulation. 2013;127:24-32

TEVAR PREVENTS AORTIC-RELATED **MORTALITY ACROSS ALL PATHOLOGIES:**

MIDTERM OUTCOMES

	Freedom from Aortic-Related Mortality [†] p<0.001	Freedom from Reintervention ^{††} p<0.001
Acute Type B Dissection	85%	46%
Chronic Type B Dissection	96%	71%
TAA	93%	84%

 $^{^\}dagger Patients \, at \, risk \, at \, 6 \, Years: \, Thoracic \, aortic \, aneurys \\ m=125, \, Type \, B \, chronic \, dissection=14, \, Type \, B \, acute \, dissection=6.$

PURPOSE

To characterize the differences in early and midterm outcomes post TEVAR in patients with thoracic aneurysms, chronic Type B aortic dissection and acute Type B aortic dissection

STUDY DESIGN

 Retrospective analysis of 5 prospective, fully monitored clinical trials, plus monitored and independently adjudicated institutional data from a single UK center that used either the Talent[™] thoracic stent graft or the Valiant[™] stent graft over an 8-year period

Medtronic

Via Martiri della Libertà 7 25030 Roncadelle (BS) Tel: +39.030.2589311

Medtronic International Ltd.

49 Changi South Avenue 2 Singapore 486056 Tel: +65.6436.5000

medtronic.com/aortic

Medtronic

710 Medtronic Parkway NE Minneapolis, MN 55432 Tel: +1.763.514.4000

Medtronic Australasia Pty Ltd.

North Ryde, NSW 2113 Australia Tel: +61.29857.9000

Medtronic International Trading Sàrl

Route du Molliau 31 CH-1131 Tolochenaz Switzerland Tel: +41.21.802.7000

Medtronic New Zealand Unit N16. Mezzanine Level 5 Gloucester Park Road Onehunga Auckland New Zealand

Medtronic of Canada Ltd.

Brampton, Ontario L6Y 0R3 Canada Tel: +1.905.460.3800

Medtronic Korea Co., Ltd.

5F, Sajo Building 1001 Daechi-dong, Kangnam-ku Seoul, 135-280 Korea

Medtronic Latin America 3750 NW 87th Avenue, Suite 700 Miami, FL 33178

Tel: +1.786.709.4200

Medtronic META FZ-LLC Office Park, Block D, 2nd Floor PO Box 500638

Dubai Internet City | Dubai, United Arab Emirates Tel: +971.4.818.2666

^{††}Patients at risk at 6 Years: Thoracic aortic aneurysm=111, Type B chronic dissection=12, Type B acute dissection=3.

Majority of deaths after TEVAR for Thoracic aortic aneurysm were due to non-aortic causes, indicative of co-morbidities.